Drug Discovery

Prothena and the Warren Center for Neuroscience Drug Discovery have entered into a collaborative research agreement to develop new small molecule therapeutics for the treatment of Alzheimer’s disease in individuals with Down syndrome. Read More

Gregor Neuert has discovered that cells respond differently to acute and gradual stress. This finding will transform how cell signaling is understood and inform the drug discovery processes. Read More

Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research. Read More

Sirenas, a San Diego-based company founded by Vanderbilt alumni Eduardo Esquenazi, BS'98, and Jake Beverage, BA'98, is applying trailblazing methods toward drug discovery. Read More

The Office of the Vice Provost for Research and the Center for Technology Transfer and Commercialization have posted informational slides for faculty preparing pre-proposal submissions in response to the inaugural Ancora request for proposals. Read More

Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature. Read More

Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development. Read More

New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers. Read More

The lasting impact of the historic partnership between the federal government and America's research universities is the topic of this week's column from Chancellor Nicholas S. Zeppos. Read More

Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia. Read More

An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy. Read More

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development. Read More

Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects. Read More

Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019. Read More

Geneticists have developed an effective new method for identifying the genes that produce the chemicals plants use to protect themselves from predators, which are an important natural drug source. Read More

A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments. Read More

Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read More

Vanderbilt University has been selected as one of seven Dedicated Centers in the nation for the next phase of the Chemical Biology Consortium (CBC), a national network of scientists on the leading edge of cancer drug discovery. Read More

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers reported May 2 in Nature Methods. Read More

A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation. Read More